Moderna, Inc: Initiation Of Coverage – Product Pipeline, Commercial Portfolio & 5 Key Drivers!

This is our first report on Moderna, Inc., a renowned biotechnology company utilizing mRNA technology in the development of therapeutics and vaccines. The company entered 2024 optimistic despite challenging 2023 results. The company’s revenue for 2023 stood at $6.1 billion, with a net loss of $4.7 billion. However, these results encompass primarily noncash charges of $3.7 billion related to the resizing of manufacturing and the tax valuation allowance. Excluding these elements, the net loss is reduced to $1.6 billion.